About Biotia
Biotia is a Healthcare company based in Brooklyn (United States) founded in 2016 by Niamh O'Hara. Sequencing-based solutions are provided for hospitals to combat infections. Biotia has raised $19.4 million across 3 funding rounds from investors including SK Square, OCA Ventures and Continuum Health Ventures. Its chief executive, as recorded, is Niamh O'Hara. Biotia offers products and services including GeoSeeq, BIOTIA-DX, BIOTIA-ID Urine, and BIOTIA-ID Joint Fluid. Its focus areas include Life Sciences, Genomics, Applied Genomics and Microbial Genomics. Its legal entity is BIOTIA, INC. Its competitors include Evelo Biosciences, PathogenDX and Manus Bio; 3 of its 3 listed competitors have raised funding.
Company details
Biotia was founded in 2016 and is based in Brooklyn, United States. Operations focus on the healthcare sector, where proprietary bioinformatics technology is utilized to address nosocomial infections and related diseases. Services include active surveillance of high-risk hospital units and incoming patients, enabling interventions to prevent illness onset. Sequencing solutions are tailored for hospital environments to support infection control efforts.
- Total Equity Funding$19.4M (USD)
in 3 rounds
- Latest Funding Round$9M (USD), Series B
Oct 2026
- InvestorsSK Square
& 13 more
Products & Services of Biotia
Biotia offers a comprehensive portfolio of products and services, including GeoSeeq, BIOTIA-DX, BIOTIA-ID Urine, and BIOTIA-ID Joint Fluid.
Detects and predicts infectious outbreaks using AI technology.
Identifies organisms with higher sensitivity than traditional methods.
Assay for detecting urinary tract infections accurately.
Tool for identifying joint infections through genomics.
Funding Insights of Biotia
Biotia has successfully raised a total of $19.4M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $9 million completed in October 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $19.4M
- Total Rounds 3
- Last Round Series B — $9M
- First Round $2.4M
(Dec 2019)
- Investors Count 14
All 3 funding rounds of Biotia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2026 | $9M | Series B | – | Convergent Ventures | |
| Aug 2022 | $8M | Series A | – | OCA Ventures | |
| Dec 2019 | $2.4M | Seed | – | Hyperplane, TAU Ventures | – |
14 investors in total: 14 institutional.
Investors in Biotia
Biotia has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include SK Square, OCA Ventures and Continuum Health Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early-stage US venture capital investments are managed. | ocaventures.com | Chicago, United States | ||
| continuumhealth.vc | ||||
Venture capital firm funding transformative technologies | phoenix-vp.com | San Mateo, United States | ||
Venture capital fund investment in tech-startups | 2021 | sksquare.com | Seoul, South Korea | |
DigitalDX Ventures is focused on AI and healthcare innovation investments. | digitaldxventures.com | Menlo Park, United States | ||
Hyperplane is engaged in providing seed capital to startups. | hyperplane.vc | Boston, United States | ||
Early-stage tech startups in Israel are supported by TAU Ventures. | 2018 | tauventures.co.il | Tel Aviv, Israel | |
Early & Expansion stage tech-focused VC firm investing in geographies such as the US | leawoodvc.com | Leawood, United States | ||
Early-stage financings are led for innovative healthcare companies. | springtide.com | |||
| convergentvc.com |
Investor details for Biotia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biotia
10 people are tracked at Biotia (6 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Niamh O'Hara | Co-Founder & CEO | Leadership |
Dorottya Nagy-Szakal MD PhD | Chief Medical Officer | Leadership |
David Danko | Chief Technology Officer | Leadership |
Mara Couto-Rodriguez | Director of Research and Development | Leadership |
Niamh B. O'Hara | CEO | Leadership |
Lorenzo Uccellini | Director Of Business Development | Leadership |
John Papciak | Junior Bioinformatic Developer | Team |
Nemcsok Tamás | Full Stack Developer | Team |
Gabor Fidler | Bioinformatics Engineer | Team |
Ford Combs | Senior Bioinformatics Engineer | Team |
Complete people profiles for Biotia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Biotia
3 dated milestones of Biotia across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Biotia is founded.
- Funding First funding round of $2.4M.
- Funding Latest funding round, Series B, of $9.0M.
Competitors of Biotia
Biotia has 3 listed competitors in our database, 3 of them funded. They include Evelo Biosciences, PathogenDX and Manus Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| evelobio.com | 2015 | Cambridge, United States | $166.5M | 117 | Therapeutics for inflammatory diseases, COVID-19, and cancer are developed. | |
| pathogendx.com | 2014 | Tucson, United States | $11.58M | 31 | Provider of DNA-based pathogen testing kits | |
| manusbio.com | 2011 | Cambridge, United States | $115.93M | Phytochemicals are developed using microbial fermentation processes. |
Detailed competitors of Biotia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biotia
The website of Biotia (biotia.io) receives about 2.3K visits a month.
- Monthly visits2.3K
▼ 36.6% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Biotia (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biotia
Complete news archive for Biotia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biotia
Biotia was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Biotia is headquartered in Brooklyn, United States. It is registered at Brooklyn, New York, United States.
Niamh O'Hara is the CEO of Biotia, as recorded in our data. They have also founded this company.
Biotia is a funded company, having raised a total of $19.4M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.4M, raised on Dec 2019.
Biotia was founded in 2016 and is based in Brooklyn, United States. Operations focus on the healthcare sector, where proprietary bioinformatics technology is utilized to address nosocomial infections and related diseases. Services include active surveillance of high-risk hospital units and incoming patients, enabling interventions to prevent illness onset. Sequencing solutions are tailored for hospital environments to support infection control efforts.
Biotia's top competitors include PathogenDX, Manus Bio and Evelo Biosciences.
Biotia offers GeoSeeq, BIOTIA-DX, BIOTIA-ID Urine, and BIOTIA-ID Joint Fluid.
Biotia has 14 investors. Key investors include SK Square, OCA Ventures, Continuum Health Ventures, Phoenix Venture Partners, and seedToB.
Biotia operates through Biotia, Inc..